Thoracic Aortic Aneurysm

1. Disease Information

1.1 Overview

A thoracic aortic aneurysm (TAA) is a permanent, localized dilation of the thoracic aorta — conventionally ≥1.5× the expected normal diameter for the patient's age, sex, and body size — involving the aortic root, ascending aorta, arch, or descending thoracic aorta. TAA is fundamentally a disease of the aortic media: progressive loss of vascular smooth muscle cells (SMCs), fragmentation of elastic lamellae, and accumulation of proteoglycan-rich ground substance ("medial degeneration") weaken the wall so that it dilates under cyclic hemodynamic load, and ultimately dissects or ruptures.

TAA differs mechanistically from abdominal aortic aneurysm (AAA). AAA is dominated by atherosclerosis, transmural inflammation, and adventitial/medial proteolysis in a vessel of neural-crest-independent origin; TAA is predominantly a non-atherosclerotic, non-inflammatory degenerative medial disease in a segment derived largely from cardiac neural crest and second heart field. This distinction is now supported at the level of human genetics: the Million Veteran Program GWAS explicitly concluded (PMID:37308786):

"We leverage multiple downstream analytic methods to identify causal TAAD risk genes and cell types and provide human genetic evidence that TAAD is a non-atherosclerotic aortic disorder distinct from other forms of vascular disease."

TAA is characteristically asymptomatic until catastrophic. Most aneurysms are found incidentally on imaging performed for another indication; the first clinical manifestation in a substantial minority is acute aortic dissection, rupture, or sudden death.

1.2 Nosological structure (important for KB modeling)

"Thoracic aortic aneurysm" is best modeled as an umbrella/complex entity that subsumes several mechanistically distinct routes to a shared final common pathway:

The proportion attributable to Mendelian disease is substantial. Renard et al. (PMID:30071989) state:

"Thoracic aortic aneurysms progressively enlarge and predispose to acute aortic dissections. Up to 25% of individuals with thoracic aortic disease harbor an underlying Mendelian pathogenic variant."

1.3 Key identifiers

1.4 Synonyms and alternative names

Thoracic aortic aneurysm; TAA; ascending thoracic aortic aneurysm (ATAA); aortic root aneurysm; annuloaortic ectasia (root-predominant, historic term); descending thoracic aortic aneurysm (DTAA); thoracoabdominal aortic aneurysm (TAAA, when it crosses the diaphragm); thoracic aortic aneurysm and dissection (TAAD) when the aneurysm-and-dissection spectrum is treated as one entity; heritable thoracic aortic disease (HTAD) for the Mendelian subset; familial thoracic aortic aneurysm and dissection (FTAAD); "aortopathy" (in BAV/connective-tissue contexts); historic pathological synonyms cystic medial necrosis / Erdheim medial degeneration — the latter formally deprecated in favor of "medial degeneration" by the Society for Cardiovascular Pathology / AECVP consensus (PMID:27031798).

1.5 Provenance of the knowledge

Information for this entry is mixed-source: - Aggregated disease-level resources: OMIM, Orphanet, ClinGen (gene-disease validity), MONDO, HPO, society guidelines (2022 ACC/AHA PMID:36334952; 2024 EACTS/STS PMID:38416090 / PMID:38408364). - Individual-patient / registry data: International Registry of Acute Aortic Dissection (IRAD; PMID:10685714, PMID:17709637), Olmsted County population cohort (PMID:9851478), Swedish national registers (PMID:17145990), Yale aortic database (PMID:11834007, PMID:16996941), UK Biobank imaging (PMID:34837083), Million Veteran Program EHR + genotype (PMID:37308786), Swedish/Danish administrative pharmacoepidemiology (PMID:29519881). - Molecular / tissue-level: surgical aortic specimens with bulk and single-cell transcriptomics (PMID:33017217), mouse genetics.

2. Etiology

2.1 Disease causal factors

The final common pathway is medial degeneration → wall weakening → dilation → dissection/rupture, reached from three broad classes of upstream lesion:

1. Extracellular matrix (ECM) / microfibril defects — the SMC cannot be properly anchored to, or signal through, its elastin-microfibril network. FBN1 (fibrillin-1), COL3A1 (type III procollagen), LOX (lysyl oxidase cross-linking), EFEMP2/FBLN4, MFAP5, THSD4/ADAMTSL6, LTBP3, BGN, ELN.
2. TGF-β signaling pathway lesions — TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2, TGFB3, SKI. Paradoxically, most are loss-of-function variants yet produce a tissue signature of increased TGF-β signaling.
3. SMC contractile apparatus defects — ACTA2 (SMC α-actin), MYH11 (SM myosin heavy chain), MYLK (myosin light chain kinase), PRKG1 (cGMP-dependent protein kinase I). Guo et al. (PMID:23910461) frame this axis explicitly:

"Gene mutations that lead to decreased contraction of vascular smooth-muscle cells (SMCs) can cause inherited thoracic aortic aneurysms and dissections."

Superimposed on all three is hemodynamic load (hypertension, abnormal BAV flow jets), aging (elastin has essentially no turnover after adolescence; medial degeneration accumulates), and inflammation in the aortitis subset.

2.2 Risk factors

2.2.1 Genetic risk factors

A. Mendelian causal genes. The ClinGen HTAAD Gene Curation Expert Panel evaluated 53 candidate genes and produced the field's reference gene list (PMID:30071989 — paraphrase: 53 genes assessed with the ClinGen framework; 11 genes assigned to the definitive + strong categories and designated "HTAAD genes," with the remainder moderate, limited, or disputed/no-evidence). The definitive/strong set:

Newer / emerging genes: THSD4 (hgnc:25835), LTBP3 (hgnc:6716), MFAP5 (hgnc:29673), FOXE3 (hgnc:3808), MAT2A (hgnc:6904), BGN (hgnc:1044, X-linked Meester-Loeys), FLNA (hgnc:3754), NOTCH1 (hgnc:7881, BAV-associated).

Gene-specific effect sizes matter clinically: ACTA2 accounts for the largest share of nonsyndromic FTAAD. Guo et al. (PMID:17994018):

"Here we show that missense mutations in ACTA2 are responsible for 14% of inherited ascending thoracic aortic aneurysms and dissections (TAAD)."

B. Common-variant / polygenic risk. The genetic architecture of sporadic TAA is polygenic. The Million Veteran Program GWAS (PMID:37308786):

"Here, we conducted a genome-wide association study (GWAS) of TAAD, testing ~25 million DNA sequence variants in 8,626 participants with and 453,043 participants without TAAD in the Million Veteran Program, with replication in an independent sample of 4,459 individuals with and 512,463 without TAAD from six cohorts. We identified 21 TAAD risk loci, 17 of which have not been previously reported."

"Our results demonstrate that the genetic architecture of TAAD mirrors that of other complex traits and that it is not solely inherited through protein-altering variants of large effect size."

Deep-learning phenotyping of UK Biobank cardiac MRI further quantified the heritable component of aortic caliber itself (PMID:34837083 — paraphrase: deep learning applied to ~4.6 million cardiac images identified 82 loci for ascending and 47 loci for descending thoracic aortic diameter; a polygenic score for ascending aortic diameter was associated with thoracic aortic aneurysm in 385,621 UK Biobank participants).

C. Chromosomal/structural risk. Turner syndrome (45,X) carries a markedly elevated risk of aortic dilation, BAV, coarctation, and dissection at diameters that would be considered normal in average-sized adults — hence the use of the aortic size index (ASI, cm/m²) rather than absolute diameter in this group. 22q11.2 deletion and Williams-Beuren (ELN) produce arteriopathy that is usually stenotic rather than aneurysmal.

D. Modifier genes. Formal modifier loci are poorly established. Candidate modifiers of the Marfan aortic phenotype include the polygenic background for aortic diameter (PMID:34837083), sex, and variants affecting TGF-β pathway dosage — the Tgfb2^+/- × Fbn1^C1039G/+ double-mutant worsening reported by Lindsay et al. (PMID:22772368) is a proof-of-principle for TGF-β-pathway gene dosage as a modifier:

"Mice that harbor both a mutant Marfan syndrome (MFS) allele (Fbn1(C1039G/+)) and Tgfb2 haploinsufficiency show increased TGF-β signaling and phenotypic worsening in association with normalization of TGF-β2 expression and high expression of TGF-β1."

2.2.2 Environmental / non-genetic risk factors

Fluoroquinolones. Pasternak et al., nationwide Swedish cohort (PMID:29519881):

"Within the 60 day risk period, the rate of aortic aneurysm or dissection was 1.2 cases per 1000 person years among fluoroquinolone users and 0.7 cases per 1000 person years among amoxicillin users. Fluoroquinolone use was associated with an increased risk of aortic aneurysm or dissection (hazard ratio 1.66 (95% confidence interval 1.12 to 2.46)), with an estimated absolute difference of 82 (95% confidence interval 15 to 181) cases of aortic aneurysm or dissection by 60 days per 1 million treatment episodes."

Mechanistic support comes from a mouse challenge study — LeMaire et al., JAMA Surgery 2018 (PMID:30046809, "Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice"), which is MODEL_ORGANISM evidence and should be tagged as such. FDA and EMA both issued warnings against fluoroquinolone use in patients with, or at risk for, aortic aneurysm. Ciprofloxacin: CHEBI:100241 ✅.

2.2.3 Protective factors

Evidence here is thin and largely inferential: - Blood-pressure control (β-blockade, ARB, strict BP targets) reduces aortic growth rate — see §12. - Statins — observational association with reduced aneurysm growth; no randomized proof in TAA. - Avoidance of isometric/maximal-exertion straining — guideline-endorsed behavioral protection, not RCT-tested. - Genetic protective factors — none established. Protective common variants at the 21 MVP loci exist by construction (each locus has a protective allele; e.g. loci near FBN1, TCF7L2, ULK4, LRP1, ELN), but no discrete "protective allele" of clinical utility has been validated. - Diabetes mellitus is inversely associated with abdominal aortic aneurysm; the protective association is weaker and less consistent for thoracic disease and should not be curated as established for TAA.

2.2.4 Gene–environment interaction

The clinically dominant G×E interaction is genotype × hemodynamic stress: - In HTAD, hypertension and exertional BP surges accelerate a genetically weakened media; this is precisely why β-blockers/ARBs plus activity restriction are prescribed on the basis of genotype, not diameter alone. - Genotype × pregnancy: vascular EDS and Loeys-Dietz carry disproportionate peripartum dissection/uterine-rupture risk. Pepin et al. (PMID:10706896): "Complications of pregnancy led to death in 12 of the 81 women who became pregnant." - Genotype × fluoroquinolone: because ciprofloxacin inhibits ECM homeostasis and increases MMP activity, guideline bodies advise avoidance specifically in HTAD/Marfan patients — an explicitly genotype-conditioned exposure recommendation. - BAV × flow: the eccentric systolic jet of a bicuspid valve imposes an asymmetric wall-shear-stress field on the convexity of the ascending aorta, where the aneurysm preferentially forms — a structural genotype interacting with a purely physical exposure.

3. Phenotypes

TAA is silent in the large majority of patients until a complication occurs. Phenotype curation should therefore be split into (a) the structural/imaging phenotype, (b) compressive/local symptoms of a large aneurysm, (c) acute complication phenotypes, and (d) syndrome-associated systemic phenotypes when a Mendelian cause is present.

3.1 Structural / imaging phenotypes (core)

3.2 Symptoms and clinical signs

Other classically described but ontology-unverified features to look up before curating: dyspnea (HP:0002094), superior vena cava syndrome, Horner syndrome from sympathetic chain compression, cough/stridor from tracheobronchial compression, back/interscapular pain (descending TAA), pulse deficit and new diastolic murmur in dissection, and Cardarelli/Oliver sign (tracheal tug).

Note on the IRAD presentation data (PMID:10685714): "While sudden onset of severe sharp pain was the single most common presenting complaint, the clinical presentation was diverse. Classic physical findings such as aortic regurgitation and pulse deficit were noted in only 31.6% and 15.1% of patients, respectively."

3.3 Laboratory abnormalities

TAA has no diagnostic laboratory test. Investigational and complication-related markers: - D-dimer — highly sensitive but non-specific for acute aortic dissection; used as a rule-out adjunct with the aortic dissection detection risk score. LOINC 48065-7 / 48066-5. - Soluble ST2, matrix metalloproteinase-9 (MMP-9), TGF-β1, tenascin-C, smooth muscle myosin heavy chain — investigational circulating biomarkers; none guideline-endorsed. - Complication markers: rising lactate and creatinine (malperfusion), troponin (coronary ostial involvement), falling hemoglobin (rupture), leukocytosis and CRP (aortitis, or the acute-phase response to dissection). - Aortitis workup: ESR, CRP, IgG4 subclass, RPR/treponemal serology, blood cultures.

3.4 Quality of life

• Pre-repair, asymptomatic: physical health-related QoL is usually near-normal, but disease-specific anxiety and activity restriction are substantial. Marfan/HTAD cohorts consistently show reduced SF-36 mental component scores, high rates of health anxiety, and career/insurance/sport-participation limitations.
• After elective repair: QoL generally returns toward population norms; the David valve-sparing root replacement is favored partly because it avoids lifelong anticoagulation (a major QoL determinant vs. mechanical composite grafts).
• After acute dissection: markedly reduced physical and mental QoL, with a high prevalence of PTSD-spectrum symptoms and persistent pain in chronic type B dissection.
• Family-level burden: cascade screening obligations, reproductive decision-making, and surveillance for children carry documented psychosocial load in HTAD families.

4. Genetic / Molecular Information

4.1 Causal genes and their functional consequences

FBN1 (hgnc:3603; OMIM 134797) — Marfan syndrome. Fibrillin-1 is the structural backbone of extracellular microfibrils and the reservoir that sequesters latent TGF-β–binding-protein (LTBP)-bound TGF-β. Both haploinsufficiency and dominant-negative mechanisms operate; cysteine-substituting missense variants in cbEGF domains (e.g. C1039G) and premature-termination alleles are the two archetypes. Judge et al. (PMID:15254584) established that haploinsufficiency alone is sufficient. The functional link from matrix to signaling is Neptune et al. (PMID:12598898):

"We show that mice deficient in fibrillin-1 have marked dysregulation of transforming growth factor-beta (TGF-beta) activation and signaling, resulting in apoptosis in the developing lung."

"These data indicate that matrix sequestration of cytokines is crucial to their regulated activation and signaling and that perturbation of this function can contribute to the pathogenesis of disease."

ACTA2 (hgnc:130) — the most common nonsyndromic FTAAD gene. Missense variants act as dominant negatives on actin filament assembly (PMID:17994018):

"Structural analyses and immunofluorescence of actin filaments in SMCs derived from individuals heterozygous for ACTA2 mutations illustrate that these mutations interfere with actin filament assembly and are predicted to decrease SMC contraction. Aortic tissues from affected individuals showed aortic medial degeneration, focal areas of medial SMC hyperplasia and disarray, and stenotic arteries in the vasa vasorum due to medial SMC proliferation."

The specific recurrent de novo ACTA2 p.Arg179His allele produces a distinct, severe multisystem disease — multisystemic smooth muscle dysfunction syndrome (PMID:20734336; paraphrase: de novo R179H causes aortic and cerebrovascular disease with fixed dilated pupils, hypotonic bladder, malrotation, gut hypoperistalsis and pulmonary hypertension). This is an important genotype–phenotype distinction to model as a subtype.

MYH11 (hgnc:7569) — TAAD with PDA, dominant-negative. (PMID:16444274):

"We now demonstrate that the disease is caused by mutations in the MYH11 gene affecting the C-terminal coiled-coil region of the smooth muscle myosin heavy chain, a specific contractile protein of smooth muscle cells (SMC). All individuals bearing the heterozygous mutations, even if asymptomatic, showed marked aortic stiffness. Examination of pathological aortas showed large areas of medial degeneration with very low SMC content."

"Abnormal immunological recognition of SM-MHC and the colocalization of wild-type and mutant rod proteins in SMC, in conjunction with differences in their coimmunoprecipitation capacities, strongly suggest a dominant-negative effect."

MYLK (hgnc:7590) — loss of function; dissection at near-normal diameter. Clinically the most important "aneurysm-negative dissection" gene (PMID:21055718):

"Both families demonstrated a similar phenotype characterized by presentation with an acute aortic dissection with little to no enlargement of the aorta."

"The p.R1480X mutation leads to a truncated protein lacking the kinase and calmodulin binding domains, and p.S1759P alters amino acids in the α-helix of the calmodulin binding sequence, which disrupts kinase binding to calmodulin and reduces kinase activity in vitro."

PRKG1 (hgnc:9414) — recurrent gain-of-function p.Arg177Gln. (PMID:23910461):

"Exome sequencing of distant relatives affected by thoracic aortic disease and subsequent Sanger sequencing of additional probands with familial thoracic aortic disease identified the same rare variant, PRKG1 c.530G>A (p.Arg177Gln), in four families. This mutation segregated with aortic disease in these families with a combined two-point LOD score of 7.88. The majority of affected individuals presented with acute aortic dissections (63%) at relatively young ages (mean 31 years, range 17-51 years)."

"Although the p.Arg177Gln alteration disrupts binding to the high-affinity cGMP binding site within the regulatory domain, the altered PKG-1 is constitutively active even in the absence of cGMP. The increased PKG-1 activity leads to decreased phosphorylation of the myosin regulatory light chain in fibroblasts and is predicted to cause decreased contraction of vascular SMCs."

LOX (hgnc:6664) — impaired elastin/collagen cross-linking. Lee et al. (PMID:27432961 — paraphrase: whole-genome sequencing in cousins with thoracic aortic disease identified a segregating LOX missense allele; a knock-in mouse recapitulated the disease). A short verbatim fragment retrieved: "Mice homozygous for the human allele died shortly after parturition from ascending aortic aneurysm and spontaneous hemorrhage." — re-verify before use.

THSD4 (hgnc:25835) / ADAMTSL6 — haploinsufficiency impairing fibrillin-1 assembly. (PMID:32855533):

"We identified five functional variants in THSD4 of which two heterozygous variants lead to a premature termination codon. THSD4 encodes ADAMTSL6 (member of the ADAMTS/L superfamily), a microfibril-associated protein that promotes fibrillin-1 matrix assembly. The THSD4 variants studied lead to haploinsufficiency or impaired assembly of fibrillin-1 microfibrils. Thsd4+/- mice showed progressive dilation of the thoracic aorta."

TGF-β axis genes. SMAD3 (PMID:21217753):

"We delineated a new syndrome presenting with aneurysms, dissections and tortuosity throughout the arterial tree in association with mild craniofacial features and skeletal and cutaneous anomalies. In contrast with other aneurysm syndromes, most of these affected individuals presented with early-onset osteoarthritis. We mapped the genetic locus to chromosome 15q22.2-24.2 and show that the disease is caused by mutations in SMAD3. ... SMAD3 mutations lead to increased aortic expression of several key players in the TGF-β pathway, including SMAD3."

TGFBR1/TGFBR2 (PMID:15731757, Loeys-Dietz syndrome). TGFB2 (PMID:22772368) crystallizes the central paradox:

"Loeys-Dietz syndrome (LDS) associates with a tissue signature for high transforming growth factor (TGF)-β signaling but is often caused by heterozygous mutations in genes encoding positive effectors of TGF-β signaling, including either subunit of the TGF-β receptor or SMAD3, thereby engendering controversy regarding the mechanism of disease."

"Taken together, these data support the hypothesis that compensatory autocrine and/or paracrine events contribute to the pathogenesis of TGF-β-mediated vasculopathies."

COL3A1 (hgnc:2201) — vascular EDS. Mostly glycine-substitution missense and splice variants in the triple-helical domain (dominant negative); haploinsufficiency (null) alleles are milder. Pepin et al. (PMID:10706896):

"Complications were rare in childhood; 25 percent of the index patients had a first complication by the age of 20 years, and more than 80 percent had had at least one complication by the age of 40. The calculated median survival of the entire cohort was 48 years. Most deaths resulted from arterial rupture."

"The types of complications were not associated with specific mutations in COL3A1."

NOTCH1 (hgnc:7881) — BAV and aortic valve disease. Garg et al., Nature 2005 (PMID:16025100).

LTBP3 (hgnc:6716) — Guo et al., AJHG 2018 (PMID:29625025, "LTBP3 Pathogenic Variants Predispose Individuals to Thoracic Aortic Aneurysms and Dissections").

4.2 Variant classification, type, and frequency

• Classification: ACMG/AMP 2015 framework, with ClinGen HTAAD VCEP gene-specific specifications now available for FBN1 and several others. PM1 hotspots exist (e.g. FBN1 cbEGF cysteines; ACTA2 R179, R258, R118; PRKG1 R177). ClinVar is the reference submission repository; ~30–40% of rare FBN1 missense submissions remain VUS.
• Variant types: FBN1 — missense (~60%, mostly cysteine-involving), nonsense/frameshift (~25%), splice (~10%), large deletions (~2–5%, requiring del/dup analysis). ACTA2, PRKG1, TGFB2/3, TGFBR1/2 — overwhelmingly missense. MYLK, LOX, THSD4, LTBP3 — enriched for truncating/loss-of-function. MYH11 — in-frame deletions and missense in the coiled-coil rod domain.
• Allele frequency: HTAD pathogenic alleles are individually ultra-rare (gnomAD AF typically 0 or <1×10⁻⁵). This is itself a useful ACMG PM2 criterion. Conversely, the 21 MVP GWAS loci are common variants of small effect (OR typically 1.05–1.25).
• Somatic vs germline: TAA-causing variants are germline. Somatic variation is not an established mechanism; however, de novo variants are common in severe syndromic HTAD (≈25% of Marfan, and the ACTA2 R179 MSMDS allele is characteristically de novo). Somatic mosaicism has been reported in mildly affected transmitting parents.
• Functional consequence summary: loss of function (FBN1 haploinsufficiency, MYLK, LOX, THSD4, LTBP3, TGFBR1/2 kinase-dead receptors); dominant negative (FBN1 cysteine missense, ACTA2, MYH11, COL3A1 glycine substitutions); gain of function (PRKG1 R177Q — constitutively active PKG-1).

4.3 Epigenetics

• Gomez et al., Cardiovasc Res 2011 (PMID:20829218, "Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms") — chromatin-level control of the SMC contractile gene program in human aneurysmal aorta.
• Gomez et al., ATVB 2013 (PMID:23814118) — Smad2-dependent protease nexin-1 overexpression distinguishes chronic aneurysm from acute dissection in human ascending aorta, with persistent Smad2 activation attributable to chromatin remodeling at the SMAD2 promoter.
• More recent work implicates HDAC9/TWIST1/MALAT1 at the chromosome 7p21 locus, SMC-specific enhancer landscape changes, and DNA-methylation differences in BAV- vs TAV-associated aortopathy. Datasets are deposited in GEO; there is no TAA-specific curated methylation resource.

4.4 Chromosomal abnormalities

• 45,X Turner syndrome — BAV, coarctation, aortic dilation, dissection at low absolute diameters. Requires ASI-based thresholds.
• 16p13.1 duplication — replicated CNV association with both thoracic and abdominal aortic aneurysm and dissection (candidate gene MYH11, which lies in the interval).
• Large FBN1 deletions/duplications detected by MLPA or CMA account for a few percent of Marfan.
• Deletion of 15q21.1 encompassing FBN1 produces Marfan with additional contiguous-gene features.

5. Environmental Information

• Occupational/toxic exposures: no strong established occupational cause. Historical/experimental interest in β-aminopropionitrile (BAPN), the lathyrogen in Lathyrus odoratus (sweet pea), which irreversibly inhibits lysyl oxidase and causes aortic rupture in exposed animals — the direct toxicological counterpart of human LOX loss-of-function alleles, and now the standard chemical component of rodent dissection models.
• Pharmacological exposures: fluoroquinolones (§2.2.2); cocaine and amphetamines as acute dissection triggers; anabolic-androgenic steroids (case-level); high-dose corticosteroids in Kawasaki/inflammatory contexts (case-level).
• Lifestyle: smoking (dose-dependent, strongest for descending TAA), uncontrolled hypertension, heavy isometric exercise/powerlifting, stimulant use. Cardiorespiratory exercise at moderate intensity is not prohibited and is guideline-permitted with BP-limited intensity.
• Infectious agents: Treponema pallidum (NCBITaxon:160) — syphilitic aortitis with saccular ascending/arch aneurysm and coronary ostial stenosis, now rare but a classic. Salmonella enterica (NCBITaxon:28901) — the most common cause of mycotic aortic aneurysm, with a predilection for atherosclerotic and diseased aortic segments. Staphylococcus aureus (NCBITaxon:1280) — mycotic aneurysm, typically post-bacteremic/endocarditic. Mycobacterium tuberculosis (NCBITaxon:1773) — contiguous spread from mediastinal nodes/spine. Coxiella burnetii, Listeria — rare.

6. Mechanism / Pathophysiology

6.1 The canonical causal chain

This is the chain the dismech module aortopathy_tgfbeta_dysregulation already encodes, and a TAA entry should declare conforms_to against its nodes:

[trigger] Aortic wall ECM defect  OR  SMC contractile-apparatus defect  OR  hemodynamic overload
↓
Impaired SMC–matrix mechanosensing / loss of contractile tone
↓
TGF-β signaling dysregulation (paradoxical increase in canonical pSmad2/3 and
noncanonical ERK1/2–JNK output; AT1R-dependent component)
↓
Medial degeneration: SMC apoptosis + phenotypic modulation, elastic fiber
fragmentation, proteoglycan/glycosaminoglycan pooling, MMP-2/MMP-9 activation
↓
Loss of tensile strength and increased wall stress (Laplace: σ ∝ P·r/2t)
↓
Progressive aortic dilation (positive-feedback: larger radius → higher wall stress)
↓
Intimal tear → aortic dissection  |  Wall failure → aortic rupture
↓
Tamponade, malperfusion, exsanguination, death

Suggested conformance targets: aortopathy_tgfbeta_dysregulation#TGF-beta Signaling Dysregulation (canonical hub), plus the medial-degeneration and dilation nodes. Note also the deliberate exclusion of atherogenesis — the MVP GWAS explicitly establishes TAAD as non-atherosclerotic (PMID:37308786), so a TAA entry should not conform to atherogenesis, unlike an AAA or coronary entry. Post-dissection thrombosis of the false lumen may justify a link to thrombogenesis.

6.2 Molecular pathways

6.3 The TGF-β paradox — and why the KB should model it as a hypothesis, not a settled fact

The founding observation is that Fbn1-deficient tissue shows excess TGF-β activity, and TGF-β antagonism rescues the phenotype. Habashi et al. (PMID:16601194):

"We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-beta signaling and can be prevented by TGF-beta antagonists such as TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation."

But the direction of the TGF-β effect is time- and context-dependent. Cook et al. (PMID:25614286, paraphrase with verbatim fragments):

"Aneurysm growth, media degeneration, aortic levels of phosphorylated Erk and Smad proteins and the average survival of Fbn1(mgR/mgR) mice were compared after a ≈3-month-long treatment with placebo and either the AT1r antagonist losartan or the TGFβ-neutralizing antibody 1D11."

"TGFβ neutralization either exacerbated or mitigated TAA formation depending on whether treatment was initiated before or after aneurysm formation."

Combined with the loss-of-function nature of TGFBR1/2, SMAD3, and TGFB2/3 variants (PMID:22772368), the field's current reading is that early TGF-β signaling is protective/homeostatic for the aortic media, and the late excess seen in diseased tissue is a compensatory, and then maladaptive, response. Curation guidance: model the "increased TGF-β signaling drives aneurysm" edge inside a mechanistic_hypotheses group (status ALTERNATIVE or EMERGING) rather than asserting it as canonical, and attach a KNOWLEDGE_GAP or HUMAN_MODEL_MISMATCH discussion — the losartan mouse result (PMID:16601194) did not translate into superiority over β-blockade in humans (PMID:25405392), which is a textbook model-to-human mismatch.

6.4 Cellular processes and cell types

Key cellular processes: SMC apoptosis and anoikis; SMC phenotypic modulation from contractile (ACTA2, MYH11, CNN1, TAGLN high) to synthetic/modulated/fibromyocyte states; impaired autophagy; senescence; mitochondrial dysfunction; adventitial neovascularization and vasa vasorum stenosis (documented in ACTA2 aortas — PMID:17994018).

6.5 Tissue-damage mechanisms

• Elastic fiber fragmentation — the diagnostic histological lesion, from mechanical fatigue on a non-renewing elastin scaffold plus elastolysis.
• Mucoid extracellular matrix accumulation — pooling of proteoglycans/GAGs (versican, aggrecan) between lamellar units; the modern consensus term replacing "cystic medial necrosis" (PMID:27031798). GAG pooling raises local Donnan swelling pressure and delaminates the media — a mechanically distinct route to intramural tear.
• SMC dropout — Zhu et al. described "large areas of medial degeneration with very low SMC content" in MYH11 aortas (PMID:16444274).
• Laplace positive feedback — wall stress rises with radius and falls with thickness; dilation therefore self-accelerates, which is why growth rate increases with size.
• Delamination/dissection — an intimal tear admits pressurized blood into the outer third of the media, creating a false lumen that propagates antegrade/retrograde.

6.6 Protein dysfunction

• Fibrillin-1 — misfolded cbEGF domains from cysteine substitutions disrupt calcium binding and domain packing, producing protease-susceptible, poorly polymerizing monomers that poison the wild-type microfibril (dominant negative); nulls simply halve microfibril output. UniProt P35555; PDB entries for cbEGF tandem repeats.
• SMC α-actin (ACTA2) — mutant monomers incorporate into and destabilize filaments; R179H additionally perturbs the actin/myosin interface across all smooth muscle beds. UniProt P62736.
• SM-MHC (MYH11) — coiled-coil rod mutations impair dimerization and thick-filament assembly. UniProt P35749.
• MLCK (MYLK) — truncation removes the kinase and CaM-binding domains; S1759P disrupts CaM binding and reduces kinase activity (PMID:21055718). UniProt Q15746.
• PKG-1 (PRKG1) — R177Q abolishes high-affinity cGMP binding and renders the kinase constitutively active, a genuine gain of function (PMID:23910461). UniProt Q13976.
• Lysyl oxidase (LOX) — loss of copper-dependent amine oxidase activity → failure of lysine-derived cross-links (desmosine/isodesmosine in elastin, pyridinoline in collagen). UniProt P28300.
• TGFBR1/2 — kinase-domain missense variants that are catalytically dead yet dominantly interfere; the tissue nonetheless shows high pSMAD2 (the paradox). UniProt P36897 / P37173.

6.7 Metabolic and biochemical changes

• Reduced elastin cross-link density (desmosine/isodesmosine); increased urinary desmosine as an elastolysis marker.
• Copper is the LOX cofactor — copper deficiency phenocopies LOX loss (relevant to the avian aortic-rupture models, §14/15).
• Homocysteine elevation (homocystinuria, CBS deficiency) interferes with cross-linking and is a Marfan phenocopy with aortic dilation and lens dislocation — an important differential.
• scRNA-seq of human ATAA highlighted an energy-metabolism lesion (PMID:33017217): "Differential gene expression data suggested the presence of extensive mitochondrial dysfunction in ATAA tissues."

6.8 Immune involvement

In degenerative and heritable TAA, inflammation is a secondary amplifier, not the initiating event — historically the field's reason for calling it "non-inflammatory degenerative" disease. However, single-cell data show a real immune shift (PMID:33017217):

"In general, ATAA tissues had fewer nonimmune cells and more immune cells, especially T lymphocytes, than control tissues did."

In aortitis (giant-cell arteritis, Takayasu, IgG4-related disease, syphilis, ANCA-associated, relapsing polychondritis, Behçet), immunity is primary: granulomatous or lymphoplasmacytic transmural infiltration destroys the media and produces aneurysm. This subset responds to immunosuppression (glucocorticoids, tocilizumab, rituximab) and should be a separately modeled etiologic arm.

6.9 Molecular profiling

Transcriptomics. Consistent findings across bulk and single-cell studies: downregulation of the contractile SMC gene program (ACTA2, MYH11, CNN1, TAGLN, MYOCD); upregulation of synthetic/ECM-remodeling genes; interferon and inflammatory signatures in dissection specimens. The landmark human scRNA-seq resource is PMID:33017217:

"We identified 11 major cell types in human ascending aortic tissue; the high-resolution reclustering of these cells further divided them into 40 subtypes. Multiple subtypes were observed for smooth muscle cells, macrophages, and T lymphocytes, suggesting that these cells have multiple functional populations in the aortic wall."

with an integrative GWAS/Hi-C finding:

"integrative analysis of our single-cell RNA sequencing data with public genome-wide association study data and promoter capture Hi-C data suggested that the erythroblast transformation-specific related gene(ERG) exerts an important role in maintaining normal aortic wall function."

Additional single-cell resources: "Dissecting the Heterogeneity of Human Thoracic Aortic Aneurysms Using Single-Cell Transcriptomics" (ATVB 2022) and the Il1rn⁺/Trem1⁺ macrophage subpopulation study (Cell Discovery 2021) — obtain PMIDs before citing.

Proteomics. Aortic-wall proteomics reproducibly shows reduced contractile and cytoskeletal proteins with increased ECM-remodeling and stress-response proteins. Plasma proteomic candidates (MMP-9, TIMP-1, TGF-β1, tenascin-C, sST2, thrombospondin) have not achieved clinical validation. PRIDE/ProteomeXchange hold the deposited datasets.

Metabolomics/lipidomics. Small human studies report altered acylcarnitines, branched-chain amino acids, and sphingolipids in TAA vs control aorta and plasma. Nothing clinically actionable; MetaboLights/Metabolomics Workbench are the repositories.

Spatial transcriptomics and multi-omics. Recent work maps the intramural gradient of SMC phenotype from intima to adventitia and localizes GAG-pooling foci. A 2023 multi-omic study of familial TAAD implicated impaired calcium transport as a dissection-predisposing lesion (PMC10607035 — retrieve PMID before citing).

Functional genomics. No large TAA-specific CRISPR screen exists. Patient-derived iPSC-derived vascular SMCs are the dominant functional platform, and importantly show lineage-specific vulnerability: neural-crest-derived iPSC-SMCs (the lineage of the ascending aorta/root) reproduce the Marfan/LDS contractile and ECM defect while lateral-plate-mesoderm-derived SMCs do not — the leading cell-autonomous explanation for why disease is segment-restricted.

7. Anatomical Structures Affected

7.1 Organ level

Primary: the thoracic aorta. UBERON:0001515 thoracic aorta ✅. Segment-specific:

Secondary organ involvement (complications): - Heart — aortic regurgitation → LV volume overload and heart failure; hemopericardium/tamponade; coronary ostial dissection → myocardial infarction. - Brain — malperfusion stroke, and in ACTA2/HTAD, independent intracranial arteriopathy (moyamoya-like, intracranial aneurysm). - Kidney, gut, spinal cord, limbs — branch-vessel malperfusion in dissection; paraplegia from artery-of-Adamkiewicz compromise (both from dissection and as a TEVAR/open-repair complication). - Lung/airway/esophagus/laryngeal nerve — compression; aorto-bronchial and aorto-esophageal fistula. - Vertebrae/sternum — erosion by chronic saccular aneurysm.

Body systems: cardiovascular (primary); respiratory, nervous, digestive, renal, musculoskeletal (secondary). In syndromic HTAD, add ocular (ectopia lentis in Marfan), skeletal (dolichostenomelia, pectus, scoliosis), integumentary (striae, translucent skin), and craniofacial (hypertelorism, bifid uvula in LDS).

7.2 Tissue and cell level

• Tunica media — the principal site. UBERON:0003618 aorta tunica media ✅ (parent UBERON:0002522 tunica media ✅). Aortic SMC tissue: UBERON:0004178 aorta smooth muscle tissue ✅.
• Tunica intima — endothelial monolayer; origin of the entry tear in dissection.
• Tunica adventitia — collagen-rich; the last barrier before free rupture; contains the vasa vasorum, whose stenosis in ACTA2 disease contributes to medial ischemia.
• Elastic lamellae — ~55–60 lamellar units in the human ascending aorta; fragmentation is the diagnostic lesion.
• Cell populations — see §6.4 (CL terms verified).

7.3 Subcellular level (GO Cellular Component)

• Extracellular matrix / microfibril — GO:0031012 (extracellular matrix), GO:0001527 (microfibril) — verify with OAK.
• Contractile fiber / stress fiber / myofilament — GO:0001725 (stress fiber), GO:0043292 (contractile fiber) — verify.
• Focal adhesion — GO:0005925 — verify.
• Mitochondrion — GO:0005739 — implicated by PMID:33017217.
• Endoplasmic reticulum — procollagen III misfolding and ER stress in vascular EDS.
• Nucleus — SMAD2/3 nuclear translocation.

7.4 Localization and laterality

The aorta is a midline unpaired structure — laterality is not applicable in the usual sense. Two spatial patterns matter instead:

1. Longitudinal segmental restriction. Disease respects the embryonic SMC-lineage boundary at the sinotubular junction (cardiac neural crest above, second heart field/somitic mesoderm below), which is why FBN1, TGFBR1/2, and ACTA2 disease is root/ascending-predominant while MYH11 and atherosclerotic disease often favor the descending segment.
2. Circumferential asymmetry. In BAV aortopathy, dilation is characteristically greatest on the greater curvature (convexity) of the ascending aorta, matching the eccentric flow jet — an asymmetric, not bilateral, lesion.

Aneurysm shape should be curated too: fusiform (circumferential, degenerative/heritable) vs saccular (eccentric outpouching; higher rupture risk per size; typical of mycotic, post-traumatic, and penetrating-ulcer aneurysms).

8. Temporal Development

8.1 Onset

Albornoz et al. quantified the familial-vs-sporadic-vs-Marfan age gradient (PMID:16996941):

"The familial TAA group was significantly younger than the sporadic group (p < 0.0001), but not as young as the MFS group (p < 0.0001) (mean ages, 58.2 versus 65.7 versus 27.4 years)."

8.2 Progression

Stages (a practical clinical staging, no formal consensus system exists):

Growth rate. Slow and nonlinear — it accelerates with diameter. Davies et al. (PMID:11834007): "The aorta grew at a mean of 0.10 cm per year." Albornoz et al. (PMID:16996941):

"Aortic growth rate was highest for the familial group (0.21 cm/y), intermediate for the sporadic group (0.16 cm/y), and lowest for the Marfan group (0.1 cm/y; p < 0.01)."

"Familial TAAs tend to grow at a higher rate, exemplifying a more aggressive clinical entity."

(The apparently low Marfan rate reflects treatment and early surgical referral, not benign biology.)

Event rates by size. Davies et al. (PMID:11834007):

"For aneurysms greater than 6 cm in diameter, rupture occurred at 3.7% per year, rupture or dissection at 6.9% per year, death at 11.8%, and death, rupture, or dissection at 15.6% per year. At size greater than 6.0 cm, the odds ratio for rupture was increased 27-fold (p = 0.0023)."

Clouse et al. (PMID:9851478):

"The cumulative risk of rupture was 20% after 5 years. Seventy-nine percent of ruptures occurred in women (P= .01). The 5-year risk of rupture as a function of aneurysm size at recognition was 0% for aneurysms less than 4 cm in diameter, 16% (95% CI, 4%-28%) for those 4 to 5.9 cm, and 31% (95% CI, 5%-56%) for aneurysms 6 cm or more."

The critical caveat — size is a poor predictor of dissection. Pape et al., IRAD (PMID:17709637):

"Maximum aortic diameters averaged 5.3 cm; 349 (59%) patients had aortic diameters <5.5 cm and 229 (40%) patients had aortic diameters <5.0 cm."

"The majority of patients with acute type A acute aortic dissection present with aortic diameters <5.5 cm and thus do not fall within current guidelines for elective aneurysm surgery. Methods other than size measurement of the ascending aorta are needed to identify patients at risk for dissection."

Also from that paper: "Marfan syndrome patients were more likely to dissect at larger diameters (odds ratio, 14.3; 95% confidence interval, 2.7 to 100; P=0.002)" — i.e., Marfan patients dissect at larger absolute diameters than the sporadic population, which is one reason the guideline threshold for Marfan is set on Z-score/relative rather than purely absolute grounds.

Course pattern: chronic and progressive with episodic catastrophic punctuation. There is no spontaneous remission — an aneurysm does not regress. The only "remission" is treatment-induced (surgical replacement of the diseased segment). Disease duration is lifelong; even after repair, the residual native aorta remains at risk, and reoperation is common (Olsson: "The cumulative incidence of thoracic aortic reoperations was 7.8% at 10 years." — PMID:17145990).

Critical intervention windows: (i) presymptomatic detection via family screening or incidental imaging; (ii) the window between reaching the surgical threshold and dissecting — the whole rationale for elective repair; (iii) pre-pregnancy counseling and root repair in HTAD women; (iv) the first 48 hours of acute type A dissection, where mortality is ~1–2% per hour untreated.

9. Inheritance and Population

9.1 Epidemiology

For dismech Prevalence records, model these with explicit measure_type — the Olmsted and Swedish figures are ANNUAL_INCIDENCE, not prevalence, and should carry prevalence_class: BAND_1_9_PER_100000 with rate_per_100000 of 10.4 / 16.3 / 9.1 respectively. Do not compare them to Orphanet point-prevalence classes.

Olsson et al. also documented rising ascertainment and improving outcomes (PMID:17145990):

"The prevalence and incidence of thoracic aortic disease was higher than previously reported and increasing. The annual number of operations increased substantially. Surgical (30-day) and long-term survival improved significantly over time to form a growing cohort of patients needing counseling, management decisions, operations, and extended postoperative surveillance."

9.2 Inheritance (for the Mendelian subset)

• Predominant mode: autosomal dominant. Albornoz et al. (PMID:16996941): "The predominant inheritance pattern was autosomal dominant (76.9%), with varying degrees of penetrance and expressivity." Applies to FBN1, TGFBR1/2, SMAD3, TGFB2/3, ACTA2, MYH11, MYLK, PRKG1, LOX, THSD4, LTBP3, COL3A1, SKI, NOTCH1.
• HPO: HP:0000006 Autosomal dominant inheritance (verify with OAK).
• Autosomal recessive: SLC2A10 (arterial tortuosity syndrome), EFEMP2/FBLN4 (cutis laxa with aortopathy), CBS (homocystinuria phenocopy). HP:0000007 (verify).
• X-linked: BGN (Meester-Loeys syndrome), FLNA. HP:0001417/HP:0001419 (verify).
• Multifactorial/polygenic: the sporadic majority — PMID:37308786 establishes a complex-trait architecture. HP:0010982 Polygenic inheritance would be the appropriate binding for a susceptibility-typed Genetic block.
• Penetrance: high but incomplete and age-dependent. Marfan aortic root dilation is nearly fully penetrant by adulthood; nonsyndromic FTAAD genes show markedly reduced penetrance (roughly 50–80% for ACTA2 by age 60; lower for MYLK and LOX). Non-penetrant obligate carriers are documented in every published FTAAD pedigree.
• Expressivity: highly variable, both between and within families — the same FBN1 allele can produce neonatal Marfan in one relative and isolated root dilation in another. Even MYH11 asymptomatic carriers show a subclinical phenotype (PMID:16444274: "All individuals bearing the heterozygous mutations, even if asymptomatic, showed marked aortic stiffness.").
• Genetic anticipation: not a feature — no repeat-expansion mechanism is involved. Apparent anticipation in pedigrees reflects ascertainment bias and improved screening in younger generations.
• Germline mosaicism: reported for FBN1 and COL3A1; recurrence risk to siblings of an apparently de novo proband is therefore not zero (empiric estimates ~1%). Somatic/gonosomal mosaicism in mildly affected transmitting parents is documented.
• De novo rate: ~25% of Marfan probands; the ACTA2 R179 MSMDS allele is characteristically de novo.
• Founder effects: no widely established TAA founder alleles. Population-specific recurrent variants have been reported in isolated cohorts (e.g. specific FBN1 alleles in Finnish, Ashkenazi, and Han Chinese series), but none rise to founder-mutation carrier-screening status.
• Consanguinity: relevant only to the AR forms (SLC2A10, EFEMP2), which are enriched in consanguineous populations of the Middle East, North Africa, and South Asia.
• Carrier frequency: not a meaningful concept for the AD forms. For AR arterial tortuosity syndrome, carrier frequency is not established outside founder pockets.

9.3 Population demographics

• Sex: Overall incidence is higher in men (Olsson: 16.3 vs 9.1 per 100,000/yr). But women have worse outcomes at any given diameter — Clouse et al. found "51% of thoracic aortic aneurysms were identified in women who were considerably older at recognition than men (mean age, 75.9 vs 62.8 years, respectively; P= .01)" and "Seventy-nine percent of ruptures occurred in women (P= .01)" (PMID:9851478). Women are systematically under-referred for elective repair because absolute-diameter thresholds derived from male-dominated cohorts are relatively too high for smaller body size — the argument for indexed thresholds.
• Ethnicity: No strong replicated ethnic gradient for TAA itself. Higher hypertension prevalence and worse BP control in Black populations in the US contribute to higher rates of aortic dissection at younger ages; a disproportionate burden of dissection in Black patients is well documented in US registry data. GWAS discovery to date is European-ancestry-weighted, though MVP included substantial African- and Hispanic-ancestry participation.
• Geography: Global; ascertainment tracks CT/echo availability. Syphilitic aortitis remains a meaningful cause in settings with high untreated syphilis prevalence. Seasonal/circadian clustering of dissection onset (winter, morning) is reproducible, with a temperature association reported in the Nordic registries (PMID:36345977).
• Age distribution: Bimodal in effect — a young, genotype-driven peak (teens–40s, HTAD) and a large late peak (65–85 y, degenerative). Descending TAA skews older than root/ascending TAA.

10. Diagnostics

10.1 Imaging (the diagnostic mainstay)

Measurement discipline matters for KB fidelity. Guidelines require reporting the technique (leading-edge-to-leading-edge in echo; inner-edge-to-inner-edge on CT/MR), the plane (double-oblique perpendicular to the centerline), and the ECG gating status. Sinus-of-Valsalva measurements should use cusp-to-commissure or cusp-to-cusp conventions consistently across serial studies. Z-scores (age/sex/BSA-adjusted) are mandatory in pediatrics and used throughout Marfan management.

Size normalization metrics: - Aortic size index (ASI) = diameter (cm) / BSA (m²) — the standard in Turner syndrome. - Aortic height index (AHI) = diameter (cm) / height (m). - Cross-sectional area / height ratio (cm²/m) — the 2022 ACC/AHA-endorsed alternative threshold; >10 cm²/m supports intervention.

10.2 Laboratory tests and biomarkers

• No diagnostic assay for TAA itself.
• D-dimer for acute dissection rule-out in combination with a low aortic dissection detection risk score (ADD-RS ≤1). Sensitive, not specific.
• Aortitis panel: ESR, CRP, IgG4, RPR/FTA-ABS, ANCA, blood cultures.
• Homocysteine / plasma amino acids to exclude homocystinuria in a Marfanoid patient.
• Circulating research biomarkers (MMP-9, TGF-β1, sST2, tenascin-C, desmosine) — none validated for clinical use.

10.3 Histopathology / biopsy

Aortic tissue is obtained at surgery, not by pre-operative biopsy. Findings, per the Society for Cardiovascular Pathology / AECVP consensus (PMID:27031798): - Medial degeneration (the preferred term): elastic fiber fragmentation and loss, mucoid ECM accumulation (translamellar and intralamellar), SMC nuclei loss, laminar medial collapse. - Grading is semiquantitative (mild/moderate/severe) for each component. - Movat pentachrome / Verhoeff-van Gieson stains for elastin, Alcian blue for GAGs. - Aortitis subtypes: granulomatous with giant cells (GCA/Takayasu), lymphoplasmacytic with storiform fibrosis and obliterative phlebitis (IgG4-RD), obliterative endarteritis of vasa vasorum with plasma cells (syphilis), suppurative (bacterial). - Immunohistochemistry: loss of ACTA2/SM-MHC staining in contractile-gene disease; IgG4/IgG plasma-cell ratio; CD68 macrophage burden.

10.4 Electrophysiology

Not diagnostic for TAA. ECG is obtained in suspected dissection primarily to detect coronary-ostial involvement (inferior STEMI pattern from right-coronary ostial dissection) and to exclude ACS as an alternative diagnosis — IRAD found the "initial chest radiograph and electrocardiogram were frequently not helpful (no abnormalities were noted in 12.4% and 31.3% of patients, respectively)" (PMID:10685714).

10.5 Genetic testing

NCIT:C15709 Genetic Testing ✅.

Recommended approach (2022 ACC/AHA, PMID:36334952; 2024 EACTS/STS, PMID:38416090 — paraphrase, verify before quoting): - Offer genetic testing to any patient with aortic root/ascending aneurysm or aortic dissection who has: syndromic features; a family history of TAAD or unexplained sudden death; young age at presentation (<60 y); or the combination with other arteriopathy. - Multigene panel (an HTAD panel of the 11 definitive/strong ClinGen genes plus the moderate-evidence genes) is the first-line test — this is precisely why the ClinGen curation (PMID:30071989) was performed. - Whole-exome sequencing (WES) — reserved for panel-negative, strongly familial cases; the discovery route for LTBP3 (PMID:29625025), PRKG1 (PMID:23910461), and THSD4 (PMID:32855533). - Whole-genome sequencing (WGS) — research/tertiary use; the discovery route for the LOX founding family (PMID:27432961). Adds deep-intronic and structural-variant detection. - Single-gene testing — only when the familial variant is known (cascade testing) or the phenotype is unambiguous (e.g. classic Marfan → FBN1). - Del/dup analysis (MLPA) — required alongside sequencing for FBN1 and COL3A1. - Chromosomal microarray — for syndromic presentations, 16p13.1 duplication, and contiguous-gene deletions of FBN1. - Karyotype — indicated in any female with unexplained aortic dilation and short stature, to detect 45,X Turner syndrome and mosaic variants. - FISH — 22q11.2 if conotruncal features are present. - mtDNA testing / repeat-expansion testing — not applicable to TAA.

Cascade family screening is as important as proband testing: guidelines recommend aortic imaging for all first-degree relatives of a TAAD proband, and genotype-directed release from surveillance for variant-negative relatives when a pathogenic familial variant is identified. Albornoz et al. (PMID:16996941): "Screening of first-order relatives of probands with TAA is essential."

10.6 Omics-based diagnostics

• RNA-seq — used for splice-variant reclassification of FBN1/COL3A1 VUS (fibroblast or blood transcript analysis). This is the highest-yield omics adjunct in current practice.
• Proteomics/metabolomics/epigenomics — research only.
• Liquid biopsy — cell-free DNA is used for post-transplant surveillance in other settings, not for TAA. No validated circulating diagnostic.

10.7 Clinical criteria and differential diagnosis

Criteria. There is no separate diagnostic criteria set for TAA itself (it is an imaging diagnosis). The relevant criteria sets are for the underlying syndromes: - Revised Ghent nosology (2010) for Marfan syndrome — aortic root Z ≥2 plus ectopia lentis, or plus a causal FBN1 variant, or plus systemic score ≥7. - 2017 International Classification of the Ehlers-Danlos Syndromes for vascular EDS. - Loeys-Dietz — clinical gestalt plus a pathogenic variant in one of the six TGF-β-pathway genes; no scored criteria. - Aortic Dissection Detection Risk Score (ADD-RS) for triage of suspected acute dissection.

Differential diagnosis:

10.8 Screening

• Cascade family screening (first-degree relatives of a TAAD proband) — the highest-yield strategy; imaging ± genotype-directed.
• Genotype-directed screening in known-variant families — including screening of children in Marfan/LDS from diagnosis.
• Turner syndrome — lifelong cardiac imaging surveillance is standard of care.
• BAV — first-degree relative echocardiographic screening is guideline-recommended.
• Population screening is NOT recommended for TAA (unlike the one-time ultrasound AAA screen in older male smokers). The 2022 guideline instead promotes systematic reporting and follow-up of incidentally detected aortic dilation on chest imaging performed for other reasons — an "opportunistic screening" model that is now a major implementation target.
• Newborn screening: not applicable. Carrier screening: not applicable (AD disease). Preimplantation genetic testing (PGT-M) and prenatal diagnosis are available for known familial pathogenic variants.

11. Outcome / Prognosis

11.1 Survival and mortality

Elective repair is the single most powerful prognostic modifier. Davies et al. (PMID:11834007):

"Elective, preemptive surgical repair restored life expectancy to normal."

"Thoracic aneurysm is a lethal disease; aneurysm size has a profound impact on rupture, dissection, and death; for counseling purposes, the patient with an aneurysm exceeding 6 cm can expect a yearly rate of rupture or dissection of at least 6.9% and a death rate of 11.8%; and elective surgical repair restores survival to near normal."

11.2 Morbidity, disability, and QoL

• Stroke — 3–8% after arch surgery; higher with dissection-related malperfusion.
• Spinal cord ischemia / paraplegia — 2–10% after extensive descending/thoracoabdominal repair (open or TEVAR); mitigated by CSF drainage and staged intercostal sacrifice.
• Acute kidney injury / dialysis — 5–15% after thoracoabdominal repair.
• Reoperation — "The cumulative incidence of thoracic aortic reoperations was 7.8% at 10 years" (PMID:17145990); higher in HTAD, where the residual native aorta continues to degenerate.
• Anticoagulation-related morbidity — bleeding and thromboembolism with mechanical composite grafts; a key reason valve-sparing techniques are preferred in young Marfan patients.
• Chronic pain, PTSD, and reduced mental-component QoL after dissection.
• QoL instruments: SF-36 and EQ-5D-5L are the standard generic measures; PROMIS domains are increasingly used; no validated TAA-specific PRO exists (a genuine gap). Marfan-specific QoL questionnaires exist but are not widely adopted.

11.3 Complications (curate as downstream nodes)

Aortic dissection (HP:0002647 ✅) → cardiac tamponade, aortic regurgitation (HP:0001659 ✅), myocardial infarction, stroke (HP:0002140 ✅), mesenteric/renal/limb malperfusion, paraplegia; aortic rupture (HP:0031649 ✅) → hemothorax, hemopericardium, exsanguination; aorto-bronchial fistula → hemoptysis (HP:0002105 ✅); aorto-esophageal fistula → hematemesis; compression syndromes (hoarseness HP:0001609 ✅, dysphagia HP:0002015 ✅, SVC obstruction, tracheal compression); mural thrombus with distal embolization; heart failure from chronic aortic regurgitation; sudden death (HP:0001699 ✅).

Recovery potential: the aneurysmal segment does not recover — surgical replacement is definitive for that segment only. The rest of the aorta continues on its natural history.

11.4 Prognostic factors and biomarkers

Established prognostic factors: - Maximal diameter (strongest single factor; PMID:11834007, PMID:9851478) — with the crucial caveat that it under-identifies dissection risk (PMID:17709637). - Growth rate — ≥0.3 cm/yr over two consecutive years, or ≥0.5 cm in one year, is an intervention trigger. - Genotype — TGFBR1/2, ACTA2 (especially R179), MYLK, PRKG1, and COL3A1 confer higher event risk at smaller diameters; this drives genotype-specific surgical thresholds. - Indexed size — ASI, aortic height index, cross-sectional area/height ratio; especially important in women, short stature, and Turner syndrome. - Family history of dissection at small diameter — an independent trigger for earlier repair. - Hypertension (PMID:17709637: OR 2.17 for dissection at <5.5 cm), female sex (PMID:9851478: 79% of ruptures), increasing age, saccular morphology, symptoms (pain = impending rupture until proven otherwise), planned pregnancy, concomitant cardiac surgery.

Prognostic biomarkers: none validated. Investigational: D-dimer (acute), MMP-9, TGF-β1, sST2, and imaging-derived biomechanical indices (peak wall stress, aortic strain/distensibility, pulse wave velocity — reduced distensibility predicts faster growth in Marfan, PMID:29631804). Machine-learning models combining geometry, biomechanics, and genotype are an active research direction and would be a good PHENOTYPE_ALGORITHM / derivation_basis: MECHANISTIC_HYPOTHESIS candidate.

12. Treatment

12.1 Pharmacotherapy

NCIT:C15986 Pharmacotherapy ✅ is the correct generic treatment_term; pair with therapeutic_agent.

The definitive medical-therapy evidence. The Pediatric Heart Network trial (PMID:25405392, paraphrase: 608 children and young adults with Marfan syndrome randomized to losartan vs atenolol at 21 centers, 2007–2011) found no significant difference in the rate of aortic-root Z-score change over 3 years between the two drugs, and no difference in aortic surgery, dissection, or death. A short verbatim fragment: "Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers."

COMPARE (PMID:23999449, paraphrase, verbatim fragment): "Aortic root dilatation rate after 3.1 ± 0.4 years of follow-up was significantly lower in the losartan group than in controls" (0.77 vs 1.35 mm), in 233 adults, with no difference in the composite clinical endpoint.

The Marfan Treatment Trialists' Collaboration individual-patient-data meta-analysis (PMID:36049495, paraphrase with verbatim fragments) reconciled the trials:

"Angiotensin receptor blockers (ARBs) and β blockers are widely used in the treatment of Marfan syndrome to try to reduce the rate of progressive aortic root enlargement characteristic of this condition, but their separate and joint effects are uncertain."

"We identified ten potentially eligible trials including 1836 patients from our search, from which seven trials and 1442 patients were eligible for inclusion in our main analyses."

"During a median follow-up of 3 years, allocation to ARB approximately halved the annual rate of change in the aortic root Z score."

"combination therapy with both ARBs and β blockers from the time of diagnosis would provide even greater reductions in the rate of aortic enlargement than either treatment alone"

Current practice conclusion: ARB and β-blocker each roughly halve the rate of aortic root Z-score progression relative to no treatment; their effects appear independent and likely additive, supporting combination therapy in Marfan syndrome. Extrapolation to non-Marfan HTAD and sporadic TAA is by inference, not direct evidence.

12.2 Pharmacogenomics

• No CPIC guideline is specific to TAA.
• CYP2C9 and VKORC1 genotype-guided warfarin dosing is CPIC Level A and directly relevant to patients receiving a mechanical composite graft (Bentall) — this is the single most actionable PGx interaction in the TAA care pathway.
• CYP2D6 poor/ultrarapid metabolizer status affects metoprolol exposure (CPIC guideline exists for metoprolol); atenolol is renally cleared and PGx-neutral, which is one practical argument for atenolol in this population.
• Losartan requires CYP2C9-mediated conversion to its active metabolite EXP3174; CYP2C9 poor metabolizers have reduced active-drug exposure. Not currently guideline-actionable, but a plausible modifier of trial heterogeneity.

12.3 Surgical and interventional treatment

NCIT:C15329 Surgical Procedure ✅; NCIT:C157839 Endovascular Aneurysm Repair ✅; NCIT:C50815 Aortic Valve Replacement ✅.

Thresholds (2022 ACC/AHA, PMID:36334952 — paraphrase; verify each before curating): ≥5.5 cm for sporadic/degenerative ascending aneurysm (Class 1); ≥5.0 cm at experienced multidisciplinary aortic-team centers (Class 2a); ≥5.0 cm in Marfan syndrome (with 4.5 cm considered where there is a family history of early dissection, rapid growth, or planned pregnancy); ≥4.5 cm for TGFBR1/TGFBR2 Loeys-Dietz; ≥4.5 cm for ACTA2 and other high-risk genotypes; concomitant repair at ≥4.5 cm when the patient is already undergoing aortic valve or other cardiac surgery; growth ≥0.3 cm/yr over two consecutive years or ≥0.5 cm in one year; cross-sectional-area-to-height ratio >10 cm²/m; ≥5.5 cm (endovascular) or ≥6.0 cm (open) for descending TAA. A major structural recommendation of the 2022 guideline is the multidisciplinary aortic team and referral to high-volume centers.

12.4 Advanced therapeutics

• Gene therapy — none clinical. Conceptually difficult: aortic SMCs are hard to transduce, the diseased protein is often a structural dominant negative requiring allele-specific knockdown, and the therapeutic window predates symptoms by decades.
• Gene editing — preclinical only. Allele-specific CRISPR knockdown of dominant-negative FBN1 and base editing of ACTA2 have been demonstrated in iPSC-SMCs.
• RNA-based — no approved ASO or siRNA. Allele-specific ASO knockdown of mutant FBN1 is a rational but unrealized target; the dismech antisense_oligonucleotide_therapy module's RNase-H paradigm would fit.
• Cell therapy — none.
• Targeted / mechanism-directed — the historical hope (TGF-β neutralization) is complicated by the dimorphic effect (PMID:25614286). Preclinically explored: ERK1/2 inhibition, NOS2 inhibition, doxycycline (MMP inhibition; failed in AAA trials), rapamycin/mTOR inhibition, resveratrol (a single-arm open-label trial in Marfan, PMID:39317438), and PPAR-γ agonism.
• Immunotherapy — applicable only to the aortitis arm: high-dose glucocorticoids, tocilizumab (IL-6R mAb, approved for GCA), methotrexate, rituximab (IgG4-RD), TNF inhibitors (Takayasu). This is a genuinely distinct therapeutic branch and should be modeled separately from degenerative TAA.

12.5 Supportive, rehabilitative, and lifestyle measures

NCIT:C15747 Supportive Care ✅; NCIT:C15372 Smoking Cessation Intervention ✅; NCIT:C15240 Genetic Counseling ✅.

• Activity modification — avoid maximal isometric exertion, heavy weightlifting, competitive contact and burst-exertion sport; moderate aerobic exercise at ~50% capacity is encouraged (deconditioning is itself harmful).
• Smoking cessation — strongest lifestyle intervention for descending TAA.
• Stimulant avoidance (cocaine, amphetamines).
• Fluoroquinolone avoidance in known HTAD.
• Pregnancy management — pre-conception root assessment, prophylactic root repair at 4.0–4.5 cm in Marfan before pregnancy, β-blockade throughout, delivery planning at an aortic center. Pregnancy is generally contraindicated in vascular EDS.
• Cardiac rehabilitation post-repair; NCIT:C15302 Physical Therapy.
• Genetic counseling — pedigree construction, cascade testing, reproductive options.

12.6 Experimental treatments (ClinicalTrials.gov)

Active and recent directions (obtain and verify NCT numbers before curating a clinical_trials block): - Combination ARB + β-blocker versus monotherapy in Marfan (the direct implication of PMID:36049495). - Irbesartan in Marfan (AIMS trial, UK — completed; showed reduced aortic root growth). - Resveratrol in Marfan (single-arm, PMID:39317438). - Rapamycin/sirolimus and mTOR inhibition — preclinical to early phase. - Rifampicin, doxycycline, and other MMP-directed repurposing — largely negative. - TEVAR versus optimal medical therapy in uncomplicated type B dissection (ADSORB, INSTEAD-XL legacy; ongoing successors). - AI/biomechanics-guided intervention timing (observational).

12.7 Treatment strategy summary

Aneurysm detected
  ├─ Determine etiology: syndromic features? family history? BAV? aortitis? infection?
  ├─ Genetic testing (HTAD panel) if young / familial / syndromic
  ├─ ALL: BP <130/80, β-blocker ± ARB, smoking cessation, activity counseling,
  │       avoid fluoroquinolones, serial imaging (interval set by size + genotype)
  ├─ Cascade imaging ± genotype screening of first-degree relatives
  └─ Meets threshold (size / indexed size / growth / genotype / symptoms /
     planned pregnancy / concomitant cardiac surgery)?
├─ Ascending/root → open repair (valve-sparing preferred if valve is good)
├─ Arch → hemiarch/total arch ± FET
└─ Descending → TEVAR (avoid as definitive therapy in HTAD) or open repair
  Aortitis arm → immunosuppression (steroids, tocilizumab, MTX, rituximab)
  Mycotic arm  → prolonged targeted antimicrobials + debridement/repair

Personalized medicine is already real here: surgical thresholds are formally genotype-stratified, which makes TAA one of the clearest examples of genomically guided procedural timing in cardiovascular medicine.

13. Prevention

13.1 Primary prevention (preventing the aneurysm)

• Hypertension control at the population level — the single highest-impact primary prevention lever for degenerative TAA.
• Tobacco control — for descending/atherosclerotic TAA.
• Syphilis control and treatment — has essentially eliminated syphilitic aortitis in high-income settings; still relevant globally.
• Reproductive prevention in HTAD — PGT-M and prenatal diagnosis for known familial pathogenic variants; the only true primary prevention for the Mendelian arm.
• Note: for genotype-positive individuals, "primary prevention" is realistically prevention of dilation, i.e. early β-blocker/ARB from diagnosis (PMID:36049495 supports treating from the time of diagnosis).

13.2 Secondary prevention (early detection)

• Cascade family imaging — first-degree relatives of every TAAD proband.
• Genotype-directed surveillance and de-escalation in known-variant families.
• Turner syndrome and BAV lifelong surveillance protocols.
• Opportunistic detection: systematic reporting and structured follow-up of incidentally noted aortic dilation on chest CT/echo done for other reasons — the highest-yield implementation gap identified by the 2022 guideline.
• No population screening program exists or is recommended (contrast: one-time abdominal ultrasound AAA screening in men aged 65–75 who have ever smoked, a USPSTF Grade B recommendation that does not extend to the thorax).

13.3 Tertiary prevention (preventing complications in those with disease)

• Serial imaging on a size- and genotype-determined interval (typically 6–12 months, more frequently near threshold or with rapid growth).
• Medical therapy (β-blocker + ARB) and strict BP control.
• Timely elective repair at the genotype-appropriate threshold — the definitive intervention.
• Post-repair lifelong surveillance of the residual native aorta.
• Endocarditis prophylaxis after prosthetic valve/graft placement.
• Pregnancy planning and peripartum aortic-center care.
• Medication avoidance list (fluoroquinolones, stimulants).
• Patient-carried medical alert identification stating the aortic diagnosis — relevant to emergency triage of chest pain.

13.4 Immunization

Not applicable to TAA pathogenesis. Routine adult vaccination (influenza, pneumococcal, COVID-19, RSV) is standard perioperative and cardiovascular care.

13.5 Genetic screening and counseling

• Carrier screening — not applicable (autosomal dominant).
• Cascade testing — the core strategy.
• PGT-M / prenatal diagnosis — available; counseling should address the variable expressivity that makes prediction of severity from genotype imperfect.
• Counseling content: 50% transmission risk for AD forms; de novo rate ~25% in Marfan with a residual ~1% sibling recurrence risk from germline mosaicism; age-dependent penetrance; the importance of continued imaging for variant-negative relatives when no familial variant has been identified.
• Providers: NSGC-credentialed genetic counselors; NCIT:C15240 Genetic Counseling ✅.

13.6 Public health and environmental interventions

• Population sodium reduction and hypertension programs.
• Tobacco control policy.
• Regulatory action on fluoroquinolone labeling (FDA/EMA warnings — already implemented).
• Emergency-systems design: regional aortic centers with rapid transfer pathways for acute type A dissection, given the ~1–2%/hour untreated mortality.
• Health-system-level clinical decision support to flag and route incidental aortic dilation findings.

13.7 Prophylaxis

Prophylactic aortic surgery is the prophylaxis — pre-emptive replacement of the aneurysmal segment before it dissects. This is the concept Davies et al. captured (PMID:11834007): "This analysis strongly supports careful radiologic follow-up and elective, preemptive surgical intervention for the otherwise lethal condition of large thoracic aortic aneurysm." Pre-pregnancy prophylactic root replacement in Marfan women with a 4.0–4.5 cm root is a specific and well-established application.

14. Other Species / Natural Disease

14.1 Taxonomy and naturally occurring disease

Per the Merck Veterinary Manual, aneurysms are rare in domestic animal species but have been reported in dogs, cats, horses, primates, turkeys, reptiles, and other exotic species.

14.2 Orthologous genes (NCBI Gene, mouse)

Fbn1 (14118), Tgfbr1 (21812), Tgfbr2 (21813), Smad3 (17127), Tgfb2 (21808), Acta2 (11475), Myh11 (17880), Mylk (107589), Prkg1 (19091), Lox (16948), Col3a1 (12825), Thsd4 (207596), Notch1 (18128). All are single-copy, high-identity orthologs — the pathway is deeply conserved. Alliance of Genome Resources and HomoloGene are the reference resources.

14.3 Comparative pathology and evolutionary conservation

• Conserved: the elastin–fibrillin–LOX cross-linking architecture, the SMC contractile unit, and TGF-β sequestration by LTBP-fibrillin are conserved across amniotes. Copper deficiency and BAPN produce aortic rupture in birds, rodents, and pigs by the same LOX-inhibition mechanism that causes human LOX-TAAD.
• Divergent: most animals do not live long enough, or at high enough systemic blood pressure with human-like bipedal hemodynamics, to develop age-related degenerative TAA. Quadrupeds have different aortic arch geometry and lower ascending-aorta wall stress. This is the central reason spontaneous TAA is a rare veterinary diagnosis but a common human one, and why engineered models rather than natural disease dominate the research literature.
• The turkey and horse are the two species where spontaneous aortic rupture is a recognized production/breeding problem, and both have been used as comparative models.

14.4 Transmission

Not applicable — TAA is non-communicable and non-zoonotic. The only pathogen-linked forms (syphilitic, salmonella mycotic) involve organisms that are separately zoonotic or human-restricted; the aneurysm itself is not transmissible.

15. Model Organisms

15.1 Mammalian genetic models (mouse — the dominant system)

15.2 Induced (non-genetic) models

• Angiotensin II infusion (osmotic minipump, typically in ApoE^−/− or hyperlipidemic mice) — the workhorse for aneurysm and dissection; produces suprarenal abdominal and ascending aortic pathology. Widely used but arguably a better AAA than TAA model.
• β-aminopropionitrile (BAPN) ± AngII — LOX inhibition plus hemodynamic stress; reliably produces thoracic aortic dissection and rupture in young mice and rats. The most-used dedicated dissection model, and the direct pharmacological mimic of human LOX loss of function.
• CaCl₂ periadventitial application, elastase perfusion — mostly AAA models; occasionally adapted to the thoracic segment.
• Copper-deficient / lathyrogen-fed avian models — historic, but the origin of lysyl oxidase biology and directly relevant to the LOX-TAAD arm.

15.3 Non-mammalian and in vitro systems

• Zebrafish (Danio rerio, NCBITaxon:7955) — fbn2b/fibrillin and tgfbr morphants and mutants for developmental vascular patterning; rapid, transparent, good for variant functional screening; but no comparable high-pressure ascending aorta, so it cannot model the mechanical disease.
• Human iPSC-derived vascular SMCs — the most translationally informative in vitro platform. Critically, patient-derived iPSC-SMCs must be differentiated through the correct developmental lineage (cardiac neural crest for the root/ascending aorta) to reveal the phenotype; lateral-plate-mesoderm-derived SMCs from the same patient may appear normal. This lineage-specificity is itself the leading mechanistic explanation of segmental disease and should be modeled as a mechanism node.
• Primary human aortic SMC and fibroblast cultures from surgical specimens.
• Aortic ring / ex vivo pressure-myograph biomechanics, and engineered vascular tissue constructs.
• Organ-on-chip models applying cyclic stretch and physiologic shear to SMC/EC co-cultures.

15.4 Model limitations (important for HUMAN_MODEL_MISMATCH curation)

1. The losartan translation failure. Mouse Fbn1^C1039G/+ data (PMID:16601194) predicted losartan superiority over β-blockade; the human trial (PMID:25405392) found no difference. This is the canonical dismech HUMAN_MODEL_MISMATCH case for this disease.
2. Direction-of-effect instability. TGF-β neutralization "either exacerbated or mitigated TAA formation depending on whether treatment was initiated before or after aneurysm formation" (PMID:25614286) — a temporal confound largely absent from human trial design.
3. Dominant human alleles behave recessively in mouse (Smad3, Lox, Fbln4), so the mouse genotype often does not match the human one.
4. Mice rarely dissect without a chemical or hemodynamic second hit — so most models capture dilation but not the clinically decisive event.
5. Scale and hemodynamics — mouse aortic diameter is ~1 mm at ~100 mmHg with a ~600 bpm heart rate; wall stress, lamellar unit number, and cycle count differ by orders of magnitude from human.
6. No model reproduces the decades-long human natural history or the age-related degenerative form that accounts for the majority of clinical TAA.

15.5 Model resources

MGI (mouse), IMPC/KOMP (null alleles for all HTAD genes), IMSR and JAX (Fbn1^C1039G/+ is JAX #012885; Fbn1^mgR is available), MMRRC, EMMA, RGD (rat BAPN models), ZFIN (zebrafish), Cellosaurus/ATCC (human aortic SMC lines), Alliance of Genome Resources, and OMIA for the bovine Marfan and turkey aortic-rupture entries.

Appendix A — Consolidated ontology term suggestions

MONDO: MONDO:0005396 thoracic aortic aneurysm ✅ (primary disease_term); MONDO:0019625 familial thoracic aortic aneurysm and aortic dissection ✅ (subtype/grouping mapping).

HPO (all OAK-verified): HP:0012727 Thoracic aortic aneurysm · HP:0004942 Aortic aneurysm · HP:0002616 Aortic root aneurysm · HP:0004970 Ascending tubular aorta aneurysm · HP:0012728 Fusiform descending thoracic aortic aneurysm · HP:0012729 Saccular descending thoracic aortic aneurysm · HP:0002647 Aortic dissection · HP:0031649 Aortic rupture · HP:0001659 Aortic regurgitation · HP:0001647 Bicuspid aortic valve · HP:0001634 Mitral valve prolapse · HP:0001643 Patent ductus arteriosus · HP:0005116 Arterial tortuosity · HP:0005112 Abdominal aortic aneurysm · HP:0000822 Hypertension · HP:0100749 Chest pain · HP:0001609 Hoarse voice · HP:0002015 Dysphagia · HP:0002105 Hemoptysis · HP:0001279 Syncope · HP:0001699 Sudden death · HP:0002140 Ischemic stroke · HP:0002326 Transient ischemic attack.

UBERON (all OAK-verified): UBERON:0001515 thoracic aorta · UBERON:0001496 ascending aorta · UBERON:0001508 arch of aorta · UBERON:0003707 sinus of Valsalva · UBERON:0000947 aorta · UBERON:0002137 aortic valve · UBERON:0003618 aorta tunica media · UBERON:0002522 tunica media · UBERON:0004178 aorta smooth muscle tissue · UBERON:0004237 blood vessel smooth muscle.

CL (all OAK-verified): CL:0000359 vascular associated smooth muscle cell · CL:0000192 smooth muscle cell · CL:0002139 endothelial cell of vascular tree · CL:0000057 fibroblast · CL:0000235 macrophage · CL:0000084 T cell.

GO (QuickGO-verified; re-run just validate-terms since the local GO db is corrupt): GO:0007179 transforming growth factor beta receptor signaling pathway · GO:0006939 smooth muscle contraction · GO:0030198 extracellular matrix organization · GO:0030199 collagen fibril organization · GO:0048251 elastic fiber assembly · GO:0004720 protein-lysine 6-oxidase activity · GO:0006954 inflammatory response · GO:0006979 response to oxidative stress · GO:0035904 aorta development · GO:0014909 smooth muscle cell migration.

NCIT (all OAK-verified): NCIT:C15986 Pharmacotherapy · NCIT:C29576 Beta-Adrenergic Antagonist · NCIT:C66930 Angiotensin II Receptor Antagonist · NCIT:C15329 Surgical Procedure · NCIT:C157839 Endovascular Aneurysm Repair · NCIT:C50815 Aortic Valve Replacement · NCIT:C202408 Computed Tomography Angiography · NCIT:C157338 Multi-detector Computed Tomography Angiography · NCIT:C190557 Magnetic Resonance Angiography · NCIT:C80404 Transthoracic Echocardiography Test · NCIT:C80405 Transesophageal Echocardiography Test · NCIT:C16525 Echocardiography Test · NCIT:C15709 Genetic Testing · NCIT:C15240 Genetic Counseling · NCIT:C15372 Smoking Cessation Intervention · NCIT:C15747 Supportive Care · NCIT:C49236 Therapeutic Procedure.

CHEBI (OLS4-verified): CHEBI:6541 losartan · CHEBI:2904 atenolol · CHEBI:5959 irbesartan · CHEBI:6904 metoprolol · CHEBI:100241 ciprofloxacin (risk factor, not treatment).

HGNC (genenames.org-verified; use lowercase hgnc: prefix in dismech): hgnc:3603 FBN1 · hgnc:11772 TGFBR1 · hgnc:11773 TGFBR2 · hgnc:6769 SMAD3 · hgnc:11768 TGFB2 · hgnc:11769 TGFB3 · hgnc:130 ACTA2 · hgnc:7569 MYH11 · hgnc:7590 MYLK · hgnc:9414 PRKG1 · hgnc:6664 LOX · hgnc:2201 COL3A1 · hgnc:13444 SLC2A10 · hgnc:10896 SKI · hgnc:3219 EFEMP2 · hgnc:29673 MFAP5 · hgnc:3808 FOXE3 · hgnc:25835 THSD4 · hgnc:6716 LTBP3 · hgnc:7881 NOTCH1 · hgnc:1044 BGN · hgnc:3327 ELN · hgnc:3754 FLNA · hgnc:6768 SMAD2 · hgnc:6770 SMAD4 · hgnc:6904 MAT2A.

Appendix B — Master citation list

Appendix C — Curation notes for the dismech entry

1. Module conformance. Declare conforms_to: "aortopathy_tgfbeta_dysregulation#TGF-beta Signaling Dysregulation" plus the medial-degeneration and progressive-dilation nodes. Do not conform to atherogenesis — PMID:37308786 explicitly establishes TAAD as non-atherosclerotic and distinct from other vascular disease. A thrombogenesis link is defensible only for false-lumen/mural thrombus nodes.
2. Grouping membership. The repo already carries a Heritable_Thoracic_Aortic_Disease grouping; the heritable subtypes of this entry should be consistent with its NECESSARY nested AND/OR phenotype criterion.
3. Model the TGF-β paradox as a hypothesis, not a fact. Use mechanistic_hypotheses with a stable hypothesis_group_id (e.g. tgfb_excess_drives_aneurysm) and opt the relevant downstream[].hypothesis_groups edges into it. Add a discussions entry with kind: HUMAN_MODEL_MISMATCH for the losartan mouse-to-human translation failure (PMID:16601194 → PMID:25405392), and a KNOWLEDGE_GAP for the unresolved direction-of-effect question (PMID:25614286, PMID:22772368).
4. Prevalence records must use measure_type: ANNUAL_INCIDENCE for the Olmsted/Swedish figures with rate_per_100000 set to 10.4 / 16.3 / 9.1 — do not enter these as point prevalence.
5. Subtypes worth modeling (short, slug-friendly name values): Sporadic, FTAAD, Marfan, LDS, vEDS, BAV-Aortopathy, Aortitis, Mycotic, MSMDS (ACTA2 R179).
6. biological_scale tags: MOLECULAR for the fibrillin/TGF-β/actomyosin nodes; CELLULAR for SMC apoptosis and phenotypic modulation; TISSUE for medial degeneration and elastic fiber fragmentation; ORGANISM for dilation, dissection, rupture, and death.
7. Frequency discipline. Most snippets above support the association only. Do not attach a frequency: enum to a phenotype unless the cited abstract carries the number — several of the abstracts here do (e.g. 21.5% familial, 14% ACTA2, 59% <5.5 cm, 27.4% mortality) and those are legitimately quotable.
8. Re-verify before committing. Quotes marked paraphrase above (Renard 30071989, Lacro 25405392, Groenink 23999449, Lee 27432961, Milewicz 20734336, Pirruccello 34837083, Pitcher 36049495, Cook 25614286) were summarized by the fetch layer and must be re-pulled with just fetch-reference PMID:xxxxx and validated with just validate-references before being used as evidence snippet: values. Everything shown in full blockquote form was retrieved verbatim from efetch.

Sources: - PubMed E-utilities (esearch/esummary/efetch) - 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease — PubMed · PMC full text - EACTS/STS Guidelines for Diagnosing and Treating Acute and Chronic Syndromes of the Aortic Organ — PubMed - Genome-wide association study of TAAD in the Million Veteran Program — Nature Genetics - Deep learning enables genetic analysis of the human thoracic aorta — Nature Genetics - Current understanding of the genetics of thoracic aortic disease — PMC - Heritable Thoracic Aortic Disease Overview — GeneReviews - Angiotensin receptor blockers and β blockers in Marfan syndrome — The Lancet - Thrombosis, Embolism, Aneurysm, and Dissection in Animals — Merck Veterinary Manual - Valve-sparing aortic root replacement (David I) in Marfan disease — EJCTS - QuickGO · OLS4 · HGNC REST · local OAK (sqlite:obo:hp, uberon, cl, ncit, mondo)